Life Sciences Fund Amsterdam
VC Fund
Amsterdam, The Netherlands
Life Sciences Fund Amsterdam is an independent venture capital fund aiming to capitalize on new technological developments in the life sciences sector. It provides investment capital to fund high tech entrepreneurial activity in the Amsterdam Metropolitan Area in general and at the academic medical centres in particular. The fund is a specialistt fund, targeting companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, medical devices and other high technology opportunities that offer venture capital returns. The Fund focuses on seed and early stage companies, but also on pre-seed commercially viable academic projects.The close collaboration between the fund, the technology transfer offices of the Life Sciences Centre Amsterdam and the Amsterdam Biomed Cluster, enables the fund to facilitate the transfer of technology to the private sector and to provide emerging technology companies and university researchers with vital seed funding and specialized financial and technical assistance. The fund started in 2007 and is now fully invested.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Life Sciences Fund Amsterdam invests in
Stages Life Sciences Fund Amsterdam invests in
Countries Life Sciences Fund Amsterdam invests in
Round sizes
Round size
- Series A
- $11M–$61M
Investment Focus
Industry
- Medical 2 (50%)
- Health Care 2 (50%)
- Biotechnology 2 (50%)
- Medical Device 2 (50%)
- Communities 1 (25%)
Stage
- Series A 2 (50%)
- Funding Round 1 (25%)
- Private Equity 1 (25%)
Country
- Ireland 1 (25%)
- United States 1 (25%)
- The Netherlands 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HiberCell is a biotechnology company developing treatments to prevent cancer relapse and metastasis. The company was founded in 2019 and is based in New York. | $60.8M / Series A / Feb 07, 2019 | ||
| Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $10.2M / May 28, 2018 | ||
| Neurent Medical is a medical device startup that develops non-surgical treatments for inflammatory sino-nasal diseases. It was founded in 2015 by Brian Shields and David Townley in Oranmore, Galway, Ireland. | $11M / Series A / May 28, 2018 | ||
| At Sigmascreening, an Amsterdam based medical device company, they focus on the development of new products in the area of breast cancer screening. Sigmascreening is established as a spin-off company from the Academic Medical Center Amsterdam (AMC Amsterdam). They have several products under development, which are all aimed at improving digitalmammography, the “golden standard†in breast cancer screening. | Private Equity / Mar 07, 2014 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Life Sciences Fund Amsterdam invest in?
Life Sciences Fund Amsterdam invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Funding Round stage. Most of the 4 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Life Sciences Fund Amsterdam's check size?
Life Sciences Fund Amsterdam typically joins rounds of $11M–$61M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Life Sciences Fund Amsterdam participates in.
When did Life Sciences Fund Amsterdam last invest?
The most recent investment recorded for Life Sciences Fund Amsterdam closed in Feb 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
